PTCT — PTC THERAPEUTICS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1070081 ·
Last close
$68.01
Market Cap
$5.68B
52W High
$90.87
52W Low
$63.18
ADV30
2,046,930
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 360,519,000 | 340,598,000 | 148,977,000 | 83,496,000 | 3,250,477,000 | 1,049,887,000 | 3,415,840,000 |
| Mar 2026 | 272,551,000 | 244,523,000 | 45,886,000 | -2,809,000 | 2,869,104,000 | 833,986,000 | 3,049,569,000 |
| Dec 2025 | 164,677,000 | 157,727,000 | -81,624,000 | -134,965,000 | 2,898,767,000 | 984,648,000 | 3,104,080,000 |
| Sep 2025 | 211,007,000 | 195,226,000 | 3,488,000 | 15,896,000 | 2,643,700,000 | 672,617,000 | 2,799,458,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-30,503,000
Investing CF
$-471,907,000
Financing CF
$536,004,000
CapEx
$-302,053,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.58
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,964,229,000
Inventory
$79,647,000
Receivables
$181,621,000
ST Investments
$960,723,000
EBIT TTM
$848,849,000
Pretax Income TTM
$696,619,000
Interest Exp TTM
$152,230,000
Analysts
15
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,008,753,984
EBITDA
$171,224,992
Free Cash Flow
$-286,804,256
Enterprise Value
$6,464,989,184
Total Cash
$2,229,082,112
Total Debt
$3,017,902,080
Shares Out
83,460,802
Trailing EPS
$-0.67
Book Value
$-2.18
ROE
—
ROA
2.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,730,655,000 | 856,508,000 | 682,644,000 | 2,898,767,000 | 3,104,080,000 | — | 711,196,000 |
| Dec 2024 | 806,780,000 | -146,747,000 | -363,295,000 | 1,705,024,000 | 2,803,095,000 | — | -107,688,000 |
| Dec 2023 | 937,822,000 | -349,402,000 | -626,604,000 | 1,895,698,000 | 2,714,253,000 | — | -158,418,000 |
| Dec 2022 | 698,801,000 | -439,925,000 | -559,017,000 | 1,705,619,000 | 2,052,705,000 | — | -356,654,000 |
TTM Snapshot
Revenues TTM
$532,105,000
NetIncome TTM
$-373,248,000
OpCashFlow TTM
$0
Assets (Latest)
$1,705,024,000
Forward EPS
$2.85
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LGND | LIGAND PHARMACEUTICALS INC | $5.76B | $287.54 | — |
| ORKA | Oruka Therapeutics, Inc. | $5.82B | $96.51 | — |
| DNTH | Dianthus Therapeutics, Inc. /DE/ | $5.84B | $106.92 | — |
| AMRX | Amneal Pharmaceuticals, Inc. | $5.85B | $18.32 | — |
| XENE | Xenon Pharmaceuticals Inc. | $6.06B | $62.67 | — |
News headlines (Yahoo Finance, 1h cache)
PTC Therapeutics Q2 Earnings Call Highlights
2026-08-01 01:02 · Yahoo
PTC Therapeutics (PTCT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
2026-07-31 13:30 · Yahoo
PTC Therapeutics Inc (PTCT) (Q2 2026) Earnings Call Highlights: Record Revenue and Raised ...
2026-07-31 05:04 · Yahoo
PTC Therapeutics (PTCT) Beats Q2 Earnings and Revenue Estimates
2026-07-30 21:25 · Yahoo
PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
2026-07-30 20:01 · Yahoo
Will PTC Therapeutics (PTCT) Report Negative Earnings Next Week? What You Should Know
2026-07-23 14:00 · Yahoo
Hamilton Lane Board Elects Michael Schmertzler as New Independent Director
2026-07-23 11:00 · Yahoo
uniQure Trends to Watch as Gene Therapy Bets Shift Beyond Hemgenix
2026-07-17 18:52 · Yahoo
QURE Stock Outlook Rests on AMT-130, FDA Talks, and Cash Runway
2026-07-17 18:25 · Yahoo
PTC Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, July 30, 2026
2026-07-16 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.